Curated News
By: NewsRamp Editorial Staff
November 19, 2025
New Breast Cancer Biomarker Predicts Chemo & Immunotherapy Success
TLDR
- The FGD3 protein biomarker discovery gives companies like Calidi Biotherapeutics a competitive edge in developing targeted immunotherapies for breast cancer patients.
- University of Illinois researchers identified the FGD3 protein through genome-wide screening as a biomarker predicting chemotherapy and immunotherapy efficacy in breast cancer.
- This biomarker discovery helps ensure breast cancer patients receive effective treatments, reducing unnecessary side effects and improving survival outcomes worldwide.
- Scientists found that a single protein can predict which breast cancer treatments will work, potentially revolutionizing personalized cancer care approaches.
Impact - Why it Matters
This discovery represents a significant advancement in personalized cancer care, potentially transforming treatment outcomes for breast cancer patients. By identifying which patients will respond to chemotherapy and immunotherapy, doctors can avoid subjecting non-responsive patients to unnecessary treatments with severe side effects, while ensuring responsive patients receive the most effective therapies sooner. This biomarker could lead to more targeted treatment approaches, reduced healthcare costs, improved quality of life during treatment, and better survival rates. For the broader medical community and pharmaceutical companies, it opens new avenues for developing more precise cancer therapies and advancing the field of precision oncology.
Summary
Researchers from the University of Illinois Urbana-Champaign have made a significant breakthrough in breast cancer treatment by discovering a protein that can predict which patients will respond well to chemotherapy and immunotherapy. Through comprehensive genome-wide screening in human cancer cells, the scientific team identified the FGD3 protein as a promising biomarker capable of determining chemotherapy and immunotherapy efficacy. This discovery represents a major advancement in precision medicine, potentially allowing oncologists to tailor treatment plans more effectively and avoid unnecessary treatments for patients unlikely to benefit from these therapies.
The research findings hold particular significance for companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) that are focused on developing innovative immunotherapies targeting various cancer types. The identification of reliable biomarkers is crucial for advancing cancer treatment development and improving patient outcomes. This breakthrough in breast cancer biomarker research could accelerate the development of more targeted and effective cancer therapies, potentially transforming how breast cancer is treated and managed in clinical practice.
The study was featured on TinyGems, a specialized communications platform that focuses on innovative small-cap and mid-cap companies with significant growth potential. TinyGems operates within the Dynamic Brand Portfolio at IBN, providing comprehensive corporate communications solutions including access to wire solutions through InvestorWire, article and editorial syndication to over 5,000 outlets, enhanced press release services, social media distribution, and tailored corporate communications solutions. The platform serves as an important resource for companies seeking to reach investors, influencers, consumers, and the general public with their breakthrough developments and corporate news.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, New Breast Cancer Biomarker Predicts Chemo & Immunotherapy Success
